We showed that the NLRP3 inhibitor, MCC950, improves measures of RV function, including tricuspid annular plane systolic excursion (TAPSE), cardiac output and ventricular-to-arterial coupling, in rats with MCT-PAH [40]. Here, NLRP3 is linked to pulmonary arterial hypertension.